On May 22, 2019, Pfizer Inc. joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the primary safety and efficacy results from the Phase 2 clinical trial. Additional details are provided on the on secondary efficacy endpoints and imaging results.

If you missed the live event, the recording can be found below.

 

Watch the Recording

About the presenters

• Shannon Marraffino
  Senior Director Rare Disease Research Unit
  Pfizer Inc.Shannon Marraffino has been working in drug development for over 25 years in a variety of capacities, primarily in clinical research. In 2013, Shannon was part of the team that initiated a healthy volunteer study of domagrozumab and then progressed the clinical development into the Duchenne patients.
• Lawrence Charnas, MD, PhD
  Executive Director, Clinical Research Rare Neurology Disease
  Pfizer Inc.Lawrence Charnas received his MD and PhD from the University of Pennsylvania, and trained at Johns Hopkins, NIH and University of Minnesota in Neurology, Genetics and Child Neurology. He has worked in drug development for 10 years in Duchenne programs, other pediatric neuromuscular diseases and a variety of clinical programs . He worked with PPMD in the first proposed draft guidance document for industry for DMD for the FDA as the industry representative on the steering committee and was previously on the board of PPMD before joining Pfizer.